Researchers have found a possible early detection method for dementia in individuals with type 2 diabetes and cardiovascular disease. That is great news for patients, but it could work out in more ways than one. A handful of companies have tried to develop Alzheimer's disease drugs, but none have been successful. The study results could provide pharmaceutical companies with a new patient population for mild to moderate Alzheimer's disease therapies. Additionally, perhaps studying the disease before it is clinically diagnosed will lead to powerful insights for its progression. In the following video, Fool contributor Maxx Chatsko explains the ramifications for several companies.
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.